AR127273A1 - BISPECIFIC ANTIBODIES THAT BIND SPECIFICALLY TO CD47 AND HER2 AND USES THEREOF - Google Patents
BISPECIFIC ANTIBODIES THAT BIND SPECIFICALLY TO CD47 AND HER2 AND USES THEREOFInfo
- Publication number
- AR127273A1 AR127273A1 ARP220102710A ARP220102710A AR127273A1 AR 127273 A1 AR127273 A1 AR 127273A1 AR P220102710 A ARP220102710 A AR P220102710A AR P220102710 A ARP220102710 A AR P220102710A AR 127273 A1 AR127273 A1 AR 127273A1
- Authority
- AR
- Argentina
- Prior art keywords
- seq
- amino acid
- acid sequence
- set forth
- her2
- Prior art date
Links
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 title abstract 6
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 title abstract 6
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 title abstract 3
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 title abstract 3
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 6
- 239000000427 antigen Substances 0.000 abstract 5
- 102000036639 antigens Human genes 0.000 abstract 5
- 108091007433 antigens Proteins 0.000 abstract 5
- 238000000034 method Methods 0.000 abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Abstract
La invención se relaciona con novedosos anticuerpos biespecíficos, que comprenden al menos un dominio de unión capaz de unirse específicamente a CD47 y al menos un dominio de unión capaz de unirse específicamente a HER2. La invención se relaciona además con métodos de producción de estos anticuerpos biespecíficos y a método de uso de los mismos. Reivindicación 1: Un anticuerpo biespecífico comprende (a) al menos un dominio de unión a antígeno capaz de unirse específicamente a CD47, y (b) al menos un dominio de unión a antígeno capaz de unirse específicamente a HER2, en donde el dominio de unión a antígeno capaz de unirse específicamente a CD47 comprende un VH y un VL, en donde el VH del dominio de unión al antígeno capaz de unirse específicamente a CD47 comprende HCDR1 que comprende o consiste en la secuencia de aminoácidos como se establece en SEQ ID Nº 11, HCDR2 que comprende o consiste en la secuencia de aminoácidos como se establece en SEQ ID Nº 12, y HCDR3 que comprende o consiste en la secuencia de aminoácidos como se establece en SEQ ID Nº 13 o 17 o 21, y el VL del dominio de unión a antígeno capaz de unirse específicamente a CD47 comprende LCDR1 que comprende o consiste en la secuencia de aminoácidos como se establece en SEQ ID Nº 14, LCDR2 que comprende o consiste en la secuencia de aminoácidos como se establece en SEQ ID Nº 15 o 18 o 22, y LCDR3 que comprende o consiste en la secuencia de aminoácidos como se establece en SEQ ID Nº 16.The invention relates to novel bispecific antibodies, which comprise at least one binding domain capable of specifically binding to CD47 and at least one binding domain capable of specifically binding to HER2. The invention also relates to methods of producing these bispecific antibodies and a method of using them. Claim 1: A bispecific antibody comprises (a) at least one antigen binding domain capable of specifically binding to CD47, and (b) at least one antigen binding domain capable of specifically binding to HER2, wherein the binding domain The antigen capable of specifically binding to CD47 comprises a VH and a VL, wherein the VH of the antigen binding domain capable of specifically binding to CD47 comprises HCDR1 comprising or consisting of the amino acid sequence as set forth in SEQ ID NO: 11 , HCDR2 comprising or consisting of the amino acid sequence as set forth in SEQ ID NO: 12, and HCDR3 comprising or consisting of the amino acid sequence as set forth in SEQ ID NO: 13 or 17 or 21, and the VL of the domain of antigen binding capable of specifically binding to CD47 comprises LCDR1 comprising or consisting of the amino acid sequence as set forth in SEQ ID NO: 14, LCDR2 comprising or consisting of the amino acid sequence as set forth in SEQ ID NO: 15 or 18 or 22, and LCDR3 comprising or consisting of the amino acid sequence as set forth in SEQ ID NO: 16.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2021122856 | 2021-10-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR127273A1 true AR127273A1 (en) | 2024-01-03 |
Family
ID=85803940
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP220102710A AR127273A1 (en) | 2021-10-09 | 2022-10-06 | BISPECIFIC ANTIBODIES THAT BIND SPECIFICALLY TO CD47 AND HER2 AND USES THEREOF |
Country Status (3)
Country | Link |
---|---|
AR (1) | AR127273A1 (en) |
TW (1) | TW202330627A (en) |
WO (1) | WO2023056970A1 (en) |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE122004000008I1 (en) * | 1991-06-14 | 2005-06-09 | Genentech Inc | Humanized heregulin antibody. |
MX2015012059A (en) * | 2013-03-15 | 2016-01-12 | Merck Patent Gmbh | Tetravalent bispecific antibodies. |
JP7022123B2 (en) * | 2016-09-30 | 2022-02-17 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | Bispecific antibody against CD3 |
CN112745392B (en) * | 2019-10-30 | 2022-07-01 | 上海洛启生物医药技术有限公司 | anti-PD-L1/CD 47 bispecific antibody and application thereof |
AR121805A1 (en) * | 2020-04-10 | 2022-07-13 | Hutchison Medipharma Ltd | ANTI-CD47 ANTIBODY AND USES OF THE SAME |
-
2022
- 2022-10-06 AR ARP220102710A patent/AR127273A1/en unknown
- 2022-10-07 TW TW111138266A patent/TW202330627A/en unknown
- 2022-10-09 WO PCT/CN2022/124084 patent/WO2023056970A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2023056970A1 (en) | 2023-04-13 |
TW202330627A (en) | 2023-08-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR110017A1 (en) | PD-1 ANTIBODIES AND USES OF THESE | |
AR100573A1 (en) | ANTIBODIES ANTI-IL-17, A METHOD FOR PRODUCING AND USING THEM | |
AR106184A1 (en) | PD-1 BINDING PROTEINS AND THEIR METHODS OF USE | |
PE20200294A1 (en) | ANTIBODIES THAT SPECIFICALLY BIND PD-1 AND METHODS OF USE | |
AR112768A1 (en) | ANTI-TIGIT ANTIBODIES | |
PE20240218A1 (en) | AFFINITY MATURED AND HUMANIZED ANTIBODIES TO FCRH5 | |
PE20210180A1 (en) | ANTI-CD33 ANTIBODIES, ANTI-CD33 / ANTI-CD3 BISPECIFIC ANTIBODIES AND USES OF THEM | |
PE20231049A1 (en) | ERIBULIN-BASED ANTIBODY-DRUG CONJUGATES AND METHODS FOR THEIR USE | |
AR095980A1 (en) | SPECIFIC BIESPECTIFIC ANTIBODIES FOR FAP (FIBROBLASTIC ACTIVATION PROTEIN) AND DR5 (DEATH RECEIVER 5), SPECIFIC ANTIBODIES FOR DR5 AND METHODS OF USE | |
CO6331370A2 (en) | ANTIBODIES AGAINST THE RECEIVER OF ADVANCED GLICOSILATION FINAL PRODUCTS (RAGE) AND USES OF THE SAME | |
CO6230999A2 (en) | ANTI-SCLEROSTINE ANTIBODY | |
AR073232A1 (en) | ANTI-IL-17A / F BISPECIFIC ANTIBODIES AND WITH CROSSED REACTIVITY | |
CL2010001544A1 (en) | Humanized monoclonal antibody or binding fragment that binds and neutralizes the human vascular endothelial growth factor (hvegf); composition that includes it; nucleic acid coding; vector; host cell; its use to treat or prevent a disease mediated by vegf; and hybridoma. | |
AR103713A1 (en) | ANTIBODIES AGAINST TAU AND ITS USES | |
AR102417A1 (en) | ANTI-TNF- / ANTI-IL-23 BIESPECTIFIC ANTIBODIES | |
PE20090161A1 (en) | MONOCLONAL ANTIBODIES ANTI CXCL13 | |
NZ609619A (en) | Novel egfr-binding molecules and immunoconjugates thereof | |
AR104906A1 (en) | ANTIBODIES DIRECTED TO THE BONE MORPHOGENETIC PROTEIN 9 (BMP9) AND METHODS FROM THESE | |
AR123480A1 (en) | THERAPEUTIC BINDING MOLECULES | |
AR114281A1 (en) | ANTI-KLK5 ANTIBODIES AND METHODS OF USE | |
CO2018001256A2 (en) | Anti-cd154 antibodies and methods to produce them | |
AR110967A1 (en) | MIMETIC ANTIBODIES FGF21 AND ITS USE | |
RU2014127287A (en) | ANTIBODIES USED FOR PASSIVE VACCINATION AGAINST INFLUENZA | |
AR123912A2 (en) | ANTIBODIES THAT BIND TGF-α AND EPIREGULIN | |
AR123083A1 (en) | PROTEINS INCLUDING HLA-G ANTIGEN BINDING DOMAINS AND THEIR USES |